January 22, 2020 / 6:18 AM / a month ago

BRIEF-Basilea Announces Agreement For Fides-03 Study With Derazantinib In Gastric Cancer

Jan 22 (Reuters) - BASILEA PHARMACEUTICA AG:

* ANNOUNCES CLINICAL SUPPLY AGREEMENT FOR ITS PLANNED STUDY FIDES-03 WITH DERAZANTINIB IN GASTRIC CANCER

* EXPECTS TO START A BIOMARKER-DRIVEN MULTI-COHORT PHASE 1/2 STUDY (FIDES-03) IN ADVANCED GASTRIC CANCER PATIENTS WITH FGFR GENETIC ABERRATIONS IN Q3 OF 2020

* STUDY WILL ASSESS EFFICACY AND SAFETY OF DERAZANTINIB AS MONO- AND COMBINATION THERAPY IN SECOND-LINE SETTING

* EXTENDED ITS CLINICAL SUPPLY AGREEMENT WITH ROCHE TO EXPLORE A COMBINATION OF DERAZANTINIB AND ATEZOLIZUMAB IN PATIENTS WITH STOMACH CANCER Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below